JP2010536396A5 - - Google Patents

Download PDF

Info

Publication number
JP2010536396A5
JP2010536396A5 JP2010522371A JP2010522371A JP2010536396A5 JP 2010536396 A5 JP2010536396 A5 JP 2010536396A5 JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010522371 A JP2010522371 A JP 2010522371A JP 2010536396 A5 JP2010536396 A5 JP 2010536396A5
Authority
JP
Japan
Prior art keywords
protein
antibody
cells
cell
interest
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010522371A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010536396A (ja
Filing date
Publication date
Priority claimed from EP07115227A external-priority patent/EP2031064A1/de
Application filed filed Critical
Publication of JP2010536396A publication Critical patent/JP2010536396A/ja
Publication of JP2010536396A5 publication Critical patent/JP2010536396A5/ja
Pending legal-status Critical Current

Links

JP2010522371A 2007-08-29 2008-08-28 タンパク質力価を増加させる方法 Pending JP2010536396A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07115227A EP2031064A1 (de) 2007-08-29 2007-08-29 Verfahren zur Steigerung von Proteintitern
PCT/EP2008/061310 WO2009027471A1 (de) 2007-08-29 2008-08-28 Verfahren zur steigerung von proteintitern

Publications (2)

Publication Number Publication Date
JP2010536396A JP2010536396A (ja) 2010-12-02
JP2010536396A5 true JP2010536396A5 (https=) 2011-10-13

Family

ID=39107125

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010522371A Pending JP2010536396A (ja) 2007-08-29 2008-08-28 タンパク質力価を増加させる方法

Country Status (6)

Country Link
US (1) US20100297697A1 (https=)
EP (2) EP2031064A1 (https=)
JP (1) JP2010536396A (https=)
KR (1) KR20100046219A (https=)
CA (1) CA2696809A1 (https=)
WO (1) WO2009027471A1 (https=)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
AU2008304748C1 (en) * 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
CA2708532C (en) 2007-12-05 2018-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-il31ra antibody and use thereof
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
EP2455403A1 (en) * 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
TWI812066B (zh) 2010-11-30 2023-08-11 日商中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
PL2702164T3 (pl) 2011-04-29 2016-06-30 Biocon Res Limited Sposób obniżania heterogeniczności przeciwciał i sposób ich wytwarzania
EP2729496B8 (en) * 2011-07-06 2017-10-18 Genmab A/S Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
JP2020141710A (ja) * 2011-07-06 2020-09-10 ゲンマブ エー／エス 抗体重鎖のｃ末端の修飾による補体依存性細胞傷害の調節
EP2729561A4 (en) 2011-07-08 2015-06-24 Momenta Pharmaceuticals Inc CELL CULTURE METHOD
US8609820B2 (en) 2011-10-28 2013-12-17 Neotope Biosciences Limited Humanized antibodies that recognize alpha-synuclein
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
EP2841589B1 (en) * 2012-04-23 2018-09-12 DSM IP Assets B.V. Polypeptide expression method
CN110563850A (zh) * 2012-04-30 2019-12-13 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
CA3081073C (en) * 2013-03-12 2023-09-12 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
US9951131B2 (en) 2013-07-12 2018-04-24 Prothena Biosciences Limited Antibodies that recognize IAPP
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
KR20160131082A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
JP6744856B2 (ja) 2014-04-08 2020-08-19 プロセナ・バイオサイエンシズ・リミテッド α−シヌクレインを認識する抗体を含む血液脳関門シャトル
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
ES2999141T3 (en) * 2015-09-01 2025-02-24 Oncoqr Ml Gmbh Coiled-coil connector
WO2017046776A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7017013B2 (ja) 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
CN110881274B (zh) 2017-05-02 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
JP2021502955A (ja) 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
CN111757730A (zh) 2017-10-06 2020-10-09 普罗塞纳生物科学有限公司 检测甲状腺素运载蛋白的方法
CU20200042A7 (es) 2017-11-29 2021-03-11 Prothena Biosciences Ltd Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EP3774879B1 (en) * 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
SG11202104549TA (en) 2018-11-08 2021-05-28 Prothena Biosciences Ltd Antibodies recognizing tau
CN119684457A (zh) 2018-11-26 2025-03-25 四十七有限责任公司 针对c-kit的人源化抗体
EP3935083A4 (en) 2019-03-03 2022-11-30 Prothena Biosciences Limited Antibodies recognizing tau
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
CA3183994A1 (en) 2020-06-24 2021-12-30 Philip James Dolan Iii Antibodies recognizing sortilin
AU2021410290A1 (en) 2020-12-24 2023-06-29 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treatment of amyotrophic lateral sclerosis
PE20241066A1 (es) 2020-12-24 2024-05-13 Eisai Randd Man Co Ltd Anticuerpo anti-epha4
AU2022388189A1 (en) 2021-11-11 2024-05-02 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
AU2024342899A1 (en) 2023-09-15 2026-04-23 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
AR133828A1 (es) 2023-09-15 2025-11-05 Prothena Biosciences Ltd Anticuerpos anti-tdp-43 y sus usos
AU2024342922A1 (en) 2023-09-15 2026-04-23 Othair Prothena Limited Cell penetrating agents and uses thereof
TW202525338A (zh) 2023-09-15 2025-07-01 愛爾蘭商普羅希那生物科學有限公司 細胞穿透劑及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1332367C (en) * 1988-09-28 1994-10-11 Richard Mark Bartholomew Method for the reduction of heterogeneity of monoclonal antibodies
GEP20074252B (en) * 2001-04-13 2007-12-10 Biogen Idec Inc Antibodies to vla-1
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
US20060024272A1 (en) * 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
EA011166B1 (ru) * 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途

Similar Documents

Publication Publication Date Title
JP2010536396A5 (https=)
CN103946372B (zh) 用于分泌产生蛋白质的方法
JP2024026255A5 (https=)
CN104011074A (zh) 用于克隆和表达关联抗体可变区基因区段的快速方法
US9458244B2 (en) Single chain multivalent binding protein compositions and methods
CN104854133A (zh) 用于制备重组抗体治疗剂的最佳重链和轻链信号肽
JP2010068806A5 (https=)
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
WO2020125120A1 (zh) 一种抗体文库的构建方法及其应用
JP2020505927A5 (https=)
CN111448314A (zh) 根据可开发性选择真核细胞展示系统中的多肽药物
CN101413002A (zh) 表达抗体或抗体类似物的重组克鲁维酵母菌及其构建方法与应用
Okazaki et al. Efficient heterologous expression and secretion in Aspergillus oryzae of a llama variable heavy-chain antibody fragment VHH against EGFR
CA2861393A1 (en) Tools and methods for expression of membrane proteins
Diepenbruck et al. Productivity and quality of recombinant proteins produced by stable CHO cell clones can be predicted by transient expression in HEK cells
JP2024037844A (ja) 試料中のポリペプチドの検出または捕捉において使用するための抗体、組成物、および試料中のポリペプチドの検出または捕捉のための方法
CN106478773B (zh) 一种人工合成的新型信号肽
EP2990485B1 (en) Fd chain gene or l chain gene each capable of increasing secretion amount of fab-type antibody
CN104558181A (zh) 靶向b淋巴瘤细胞的人源单链抗体
EP3159411B1 (en) Vector comprising gene fragment for enhancement of recombinant protein expression and use thereof
US10793619B2 (en) Preparation and selection of cells for producing bispecific antibodies
US20200010810A1 (en) Methods and compositions for inducible extracellular membrane capture of monoclonal immunoglobulins secreted by hybridomas
CN106478774B (zh) 一种用于蛋白质表达的信号肽
LT2005043A (en) Process for preparing monoclonal antibodies; hybridoma cell lines generated by this process and recombinant chimeric virus-like particles with inserted foreign protein fragments as immunogenes to generate hybridomas by this process
CN115572331A (zh) 一种具有增强FcRn受体结合的突变子